Literature DB >> 15904978

P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer.

Paul W Wirtz1, Bethan Lang, Francesc Graus, Arn M J M van den Maagdenberg, Albert Saiz, Pia A de Koning Gans, Albert Twijnstra, Jan J G M Verschuuren.   

Abstract

To assess the survival impact of the presence of P/Q-type calcium channel antibodies in patients with small cell lung carcinoma (SCLC), we examined the frequency of the antibodies and Lambert-Eaton myasthenic syndrome (LEMS) in 148 consecutive patients with SCLC, and in 30 patients with paraneoplastic cerebellar degeneration and SCLC, and studied their relation with survival. In both series, only patients with LEMS had a remarkably long survival, whereas presence of the antibodies without LEMS did not result in a better prognosis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15904978     DOI： 10.1016/j.jneuroim.2005.04.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  15 in total

1.  Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Authors:  M Hardy-Werbin; O Arpí; A Taus; P Rocha; D Joseph-Pietras; L Nolan; S Danson; R Griffiths; M Lopez-Botet; A Rovira; J Albanell; C H Ottensmeier; E Arriola
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 2.  Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.

Authors:  Ronnyson Susano Grativvol; Wagner Cid Palmeira Cavalcante; Luiz Henrique Martins Castro; Ricardo Nitrini; Mateus Mistieri Simabukuro
Journal:  Curr Oncol Rep       Date:  2018-11-10       Impact factor: 5.075

3.  Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study.

Authors:  Paul Gozzard; Mark Woodhall; Caroline Chapman; Anjan Nibber; Patrick Waters; Angela Vincent; Bethan Lang; Paul Maddison
Journal:  Neurology       Date:  2015-06-24       Impact factor: 9.910

4.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

Review 5.  Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

Authors:  Benedikt Schoser; Bruno Eymard; Joe Datt; Renato Mantegazza
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

6.  Paraneoplastic neurological syndrome in a patient with gastric cancer.

Authors:  Hitoshi Murakami; Yasushi Rino; Shoji Yamanaka; Yasuhisa Baba; Takashi Sekiguchi; Norio Yukawa; Takashi Oshima; Nobuhiro Sugano; Hitoshi Matsuura; Munetaka Masuda; Toshio Imada
Journal:  Gastric Cancer       Date:  2010-09-05       Impact factor: 7.370

7.  Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo.

Authors:  Yaping Joyce Liao; Parsa Safa; Yi-Ren Chen; Raymond A Sobel; Edward S Boyden; Richard W Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-13       Impact factor: 11.205

Review 8.  Update on neurological paraneoplastic syndromes.

Authors:  Romana Höftberger; Myrna R Rosenfeld; Josep Dalmau
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

9.  Unusual paraneoplastic syndromes of breast carcinoma: a combination of cerebellar degeneration and Lambert-Eaton Myasthenic Syndrome.

Authors:  L Romics; B McNamara; P A Cronin; M E O'Brien; N Relihan; H P Redmond
Journal:  Ir J Med Sci       Date:  2008-11-13       Impact factor: 1.568

Review 10.  The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma.

Authors:  Sarah Ew Briggs; Paul Gozzard; Denis C Talbot
Journal:  Immunotargets Ther       Date:  2013-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.